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Abstract 
Background: Screening for coronary artery disease (CAD) remains broadly performed in patients with type 2 diabe‑
tes (T2DM), although the lack of evidence. We conduct a real‑world evidence (RWE) study to assess the risk of major 
clinical outcomes and economic impact of routine CAD screening in T2DM individuals at a very high cardiovascular 
risk.
Methods: SCADIAB is a comparative nationwide cohort study using data from the French National Health Data 
System. The main inclusion criteria are: age ≥ 40 years, DT2 diagnosed for ≥ 7 years, with ≥ 2 additional cardiovascu‑
lar risk factors plus a history of microvascular or macrovascular disease, except CAD. We estimated ≥ 90,000 eligible 
participants for our study. Data will be extracted from 01/01/2008 to 31/12/2019. Eligible participants will be identi‑
fied during a first 7‑year selection period (2008–2015). Each participant will be assigned either in experimental (CAD 
screening procedure during the selection period) or control group (no CAD screening) on 01/01/2015, and followed 
for 5 years. The primary endpoint is the incremental cost per life year saved over 5 years in CAD screening group versus 
no CAD screening. The main secondary endpoints are: total 5‑year direct costs of each strategy; incidence of major 
cardiovascular (acute coronary syndrome, hospitalization for heart failure, coronary revascularization or all‑cause 
death), cerebrovascular (hospitalization for transient ischemic attack, stroke, or carotid revascularization) and lower‑
limb events (peripheral artery disease, ischemic diabetic foot, lower‑limb revascularization or amputation); and the 
budget impact for the French Insurance system to promote the cost‑effective strategy. Analyses will be adjusted for a 
high‑dimension propensity score taking into account known and unknown confounders. SCADIAB has been funded 
by the French Ministry of Health and the protocol has been approved by the French ethic authorities. Data manage‑
ment and analyses will start in the second half of 2021.
Discussion: SCADIAB is a large and contemporary RWE study that will assess the economic and clinical impacts 
of routine CAD screening in T2DM people at a very high cardiovascular risk. It will also evaluate the clinical practice 
regarding CAD screening and help to make future recommendations and optimize the use of health care resources.
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Background
Type 2 Diabetes mellitus (T2DM) is a major public health 
problem, responsible for a wide range of clinical, eco-
nomic and societal issues [1–4]. Despite the substantial 
improvement in cardiovascular prognosis observed in 
recent decades, cardiovascular disease, essentially coro-
nary artery disease (CAD), remains the leading cause 
of death [5]. CAD is often severe and silent in patients 
with T2DM [6–10], which may encourage a systematic 
and broad screening in asymptomatic individuals. Pre-
vious randomized controlled trial (RCT) did not pro-
vide evidence that routine screening for silent CAD may 
reduce the incidence of major cardiovascular events and 
death in people with T2DM [11–15]. Only one previous 
study showed that screening for silent CAD, compared 
with no screening, was associated with a reduced risk 
of minor cardiovascular events in T2DM patients with 
at least 2 cardiovascular risk factors [16]. However, the 
Trial registration ClinicalTrials.gov Identifier: NCT04534530 (https ://clini caltr ials.gov/ct2/show/NCT04 53453 0)
Keywords: Type 2 diabetes, Coronary artery disease, Cardiovascular risk, Major adverse cardiac events, Screening, 
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Table 1 Randomized controlled trials evaluating the effect of systematic screening of coronary artery disease in the risk of major 
cardiovascular adverse events in people with diabetes
T2DM type 2 diabetes mellitus, T1DM type 1 diabetes mellitus, CV cardiovascular, MI myocardial infarction, HH heart failure
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results of this monocentric and small sized study have 
never been corroborated by subsequent RCTs, although 
larger, multicentric and testing hard and validated clini-
cal outcomes (major cardiovascular events and all-cause 
death) (Table  1). The DIAD (Detection of Ischemia in 
Asymptomatic Diabetics) study showed a compara-
ble 4.8-year incidence of major cardiovascular event (a 
composite of cardiovascular death or non-fatal myocar-
dial infarction) in 1123 T2DM participants who expe-
rienced CAD screening compared with those who did 
not [11]. Similar findings were reported in further large 
multicenter RCTs and a meta-analysis [12–15]. Never-
theless, some uncertainties remain in terms of benefit of 
CAD screening strategy in T2DM patients at very high 
cardiovascular risk, particularly those with peripheral 
atherosclerosis, chronic kidney disease (CKD) or any 
microvascular disease.
Despite this lack of evidence, most of guidelines 
recommend systematic screening for silent CAD in 
asymptomatic individuals with diabetes and high or 
very high cardiovascular risk [17–20]. Hence, a major-
ity of physicians practice routine screening for silent 
CAD in patients with diabetes. We conducted a pre-
liminary survey (unpublished data) in France in 2019 
to determine the practices of 605 physicians in terms 
of screening for silent CAD in T2DM patients at a 
very high cardiovascular risk. A majority of partici-
pants (80% of cardiologists and 69% of diabetologists) 
reported a routine CAD screening practice with a 
sustained frequency: once a year (42%), once/2  years 
(20%), and once/3 years (33%).
A routine CAD screening induces high healthcare 
expenses as it leads to invasive investigations, endovas-
cular and surgical revascularizations as well as inten-
sification of pharmacological therapies. To the best of 
our knowledge, the cost-effectiveness of routine CAD 
screening has not been evaluated prospectively in popu-
lation with T2DM and a very high cardiovascular risk. 
Only two economic studies, based on Markov mod-
els, have addressed this question by comparing differ-
ent strategies in Japanese and American populations: 
no screening, screening (with stress echocardiography, 
myocardial scintigraphy coupled with stress test, or 
stress electrocardiogram) [21, 22]. Their results were 
very limited by model’s hypothesis; uncertainty sur-
rounding epidemiological and utilities data used; and 
costs of care, which may differ greatly across countries. 
In this context of discrepancy between lack of evidence 
and current guidelines and clinical practice, we aim to 
estimate the effectiveness and cost-effectiveness of sys-
tematic CAD screening in patients with T2DM and a 
very high cardiovascular risk.
Methods
Study overview and design
The Cost-effectiveness of Screening of Coronary Artery 
disease in patients with type 2 DIABetes at a very high 
cardiovascular risk (SCADIAB) study is a retrospective 
and comparative real-world evidence (RWE) cohort 
study using data from the French National Health 
Data System (SNDS, Système National des Données de 
Santé), a claim database encompassing 98,8% of the 
whole French population [23].
Study population
Inclusion criteria
Eligible participants must meet all of the following 
criteria:
Age = 40 years or older,
Affiliation to the general health insurance scheme 
in France,
Diagnosis of T2DM,
Duration of T2DM ≥ 7 years,
Two or more additional cardiovascular risk fac-
tors (obesity, hypertension, hypercholesterolemia, 
or tobacco smoking using the chronic obstructive 
pulmonary disease (COPD) as a proxy),
At least one microvascular or macrovascular dis-
ease: carotid stenosis, transient ischemic attack 
(TIA), stroke, lower-limb peripheral artery dis-
ease (PAD), CKD, severe diabetic retinopathy with 
requirement of laser photocoagulation, or periph-
eral or autonomic diabetic neuropathy.
Diagnosis will be determined based on the list of 
100% health insurance coverage for chronic diseases in 
France (including T2DM, hypertension, TIA, stroke, 
PAD, CKD, COPD), the history of diseases of interest or 
surgery (coronary, carotid or lower-limb revasculariza-
tion, bariatric surgery, kidney transplantation) accord-
ing to the International Classification of Diseases Code 
Tenth Revision (ICD-10) (Additional file  1: Table  S1), 
or at least 3 deliveries of one or more corresponding 
drugs as appropriate (antidiabetic, anti-obesity, antihy-
pertensive or lipid-lowering drugs) over one year.
Exclusion criteria
One of the following:
The presence of CAD (defined as a history of acute 
coronary syndrome, coronary revascularization, 
angina pectoris, or unstable angina).
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Any visit to an emergency department for chest 
pain resulting for admission to a cardiac intensive 
care unit.
Recruitment of participants and follow‑up
The data will be extracted from January 1, 2008 to 
December 31, 2019. A selection period will be defined by 
the 7 years (January 1, 2008 to December 31, 2014) pre-
ceding the index date. It will enable us to identify eligible 
patients and measure all the variables needed for the cal-
culation of the high dimension propensity score (hdPS). 
Each participant will be assigned to one of the two study 
groups on the index date (January 1, 2015), and then fol-
lowed up to December 31, 2019 (Fig. 1).
Study groups and methods of CAD screening
Screening group
Individuals who had at least one screening exam (stress 
electrocardiogram test, stress echocardiography, 
myocardial scintigraphy coupled with stress test or 
pharmacological stimulation using adenosine, or coro-
nary CT scan) (Table  2) during the selection period 
(2008–2015).
No‑screening group
Participants who never experienced a screening exam as 




The incremental cost per life year saved over 5  years in 
CAD screening group versus no CAD screening.
Secondary endpoints
Economic endpoints
(1) A cost-consequence analysis linking the total 5-year 
direct costs of each strategy (drugs, medical visits, hos-
pitalizations, nursing visits, biological and radiological 
Fig. 1 Study design
Table 2 Codes used to identify tests to screen coronary artery disease
Tests Procedure codes
Stress test DKRP004, EQRP002, EQRM001
Myocardial scintigraphy coupled with stress test or pharmacological stimulation using adenosine DAQL001, DAQL010, DAQL011, DAQL009
Stress echocardiography DAQM003, DZQM002, DBQM001
Coronary CT scan ECQH010
Procedure codes: Codes of the French classification of medical procedure (CCAM)
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exams, technical exams, medical transports…) and the 
total number of major cardiovascular and renal events 
over 5 years; (2) the budget impact (in €) for the French 
Insurance system to promote the most cost-effective 
strategy between routine CAD screening and no screen-
ing; and (3) the total care consumption over the follow-
up period.
Clinical endpoints
The effects of CAD screening (versus no CAD screen-
ing) in terms of major adverse cardiac events (the first 
occurrence of any component of the composite out-
come, which comprise acute coronary syndrome, coro-
nary revascularization, hospitalization for heart failure 
or all-cause death); major cerebrovascular events (the 
first occurrence either of stroke, hospitalization for TIA, 
or carotid revascularization); major adverse limb events 
(the first occurrence of any component of the composite 
outcome, comprising PAD, ischemic diabetic foot, lower-
limb revascularization (angioplasty or surgery) or ampu-
tation); and CKD or end-stage kidney disease (ESKD, 
defined as requirement of any sustained renal replace-
ment therapy or kidney transplantation). Each compo-
nent of these composite endpoints will also be considered 
individually. Major cerebrovascular events, major adverse 
limb events and ESKD will be considered during follow-
up among participants without a history of each appro-
priate condition at baseline. Clinical endpoints will be 
determined according to ICD-10 and codes of the French 
classification of medical procedure (CCAM) as presented 
in Additional file 2: Table S2.
Finally, SCADIAB study will also assess the frequency 
of routine CAD screening, expressed as the number of 
examinations performed per individual per year.
Statistical considerations
Sample size estimation
Among 3.3 million people treated for diabetes mellitus 
in France, at least 3 million are estimated to have T2DM. 
Based on previous data, about 2.4 million T2DM indi-
viduals would be free of a history of CAD, 38% would 
have at least two cardiovascular risk factors, and a his-
tory of microvascular or macrovascular disease would be 
present in more than 10% of patients [24, 25]. Hence, we 
estimated that at least 90,000 patients would be eligible 
for our study.
Statistical analysis plan
The data will be analysed by the biostatistician of the 
“Clinical Epidemiology Unit” of the University Hospital 
of Bordeaux (USMR). Analyses will be performed using 
SAS® software, version 9.4 or later (SAS Institute, Cary, 
NC, USA, http://www.sas.com) and all tests will be per-
formed at the first-order error risk α = 5%. The flow-chart 
(CONSORT), as well as the characteristics of patients 
at inclusion (eligibility criteria, epidemiological, clinical, 
biological characteristics and treatment use) will be pre-
sented. Confounding factors will be taken into account 
through a hdPS score that will involve around 500 vari-
ables, according to the Bross formula [26]. A princi-
pal component analysis will then allow us to reduce the 
dimensionality to 30 components, and the goodness 
of fit of this hdPS score will be estimated by a graphical 
comparison of the score distribution and by standard-
ized mean differences between the two study groups [27]. 
Comparisons between the two groups will be carried out 
with and without adjustment for the hdPS score, and the 
hypotheses of the different regression models chosen, 
will be systematically verified.
Regarding the analysis of the primary endpoint, a gross 
estimate of the incremental cost per life-year gained at 
5  years will be conducted. The confidence interval (CI) 
of this incremental cost-effectiveness ratio will be esti-
mated by boostrap (5000 iterations). The analysis will be 
performed as Intent to Treat. To investigate a possible 
relationship between the frequency of screening and sur-
vival, we will define four different subgroups: screening 
conducted at least once a year, less than once a year (and 
at least once every two years), less than once every two 
years (and at least once every three years), and only once 
during the follow-up period.
A cost-consequence analysis will be performed linking 
results of all direct costs (observed during the following 
period) and results on major cardiovascular events. A 
budget impact analysis will be conducted to determine 
the public expenses of the spread of a systematic screen-
ing for silent ischemic CAD.
Cardiovascular events will be expressed as numbers, 
cumulative incidence and incidence rates. Kaplan–Meier 
curves will be elaborated to plot the incidence of end-
points according to study groups (CAD screening versus 
no screening). Unadjusted comparisons between groups 
will be done using a log-rank test. Cox proportional haz-
ards regression models will be computed to estimate 
Hazard ratios, with related 95% CIs, after adjustment for 
hdPS score.
Study progress
The study protocol has been approved by the French 
ethic authorities (see “Declarations” section below). Pro-
cedures and contracts for access to the SNDS databases 
are in progress. Data management and analyses will start 
in the second half of 2021, and the main results will be 
published in 2022.
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Discussion
We will conduct a large RWE study to investigate the 
risk of major clinical outcomes and economic impact of 
routine CAD screening in individuals with T2DM and a 
very high risk for cardiovascular disease in France. We 
will perform a retrospective analysis using the electronic 
health record (EHR) data from the SNDS databases 
which represent almost the entire French population 
allowing us sufficient sample size to address the investi-
gated question.
Screening for silent CAD and risk of major cardiovascular 
events
Previous RCTs demonstrated no clinical benefit asso-
ciated with routine CAD screening in asymptomatic 
T2DM patients, but population with a high cardiovascu-
lar burden and any organ vascular damage has not been 
investigated [11–14]. Also, the observed incidence of out-
comes was much lower than expected in published RCTs 
evaluating the interest of routine CAD screening in indi-
viduals with T2DM (Table  1). The conduction of a new 
prospective RCT will be too expensive, time-consuming 
with difficulties for recruiting asymptomatic participants 
with a very high cardiovascular risk. Indeed, the DYNA-
MIT (Do You Need to Assess Myocardial Ischemia in 
Type-2 diabetes) study was stopped prematurely due to 
difficulties in recruitment of participants and a low inci-
dence of cardiovascular events [12]. DYNAMIT included 
only one-fifth (631/3000) of the originally planned enrol-
ment to detect a 20% relative risk reduction (RRR) in the 
primary endpoint (a composite of all-cause death, non-
fatal myocardial infarction, non-fatal stroke, or heart 
failure requiring hospitalization or visit to emergency 
department) in people with T2DM at a high cardiovascu-
lar risk (aged 55 to 75 years with at least 2 other cardio-
vascular risk factors). A recent meta-analysis estimated 
that a large number of participants would be needed to 
demonstrate a potential benefit of the systematic CAD 
screening strategy to reduce the incidence of major car-
diovascular events [15]. The optimal sample size for 20% 
RRR of major cardiac events should be 29,763 partici-
pants (19,548 for all-cause death). Therefore, a retrospec-
tive RWE study seems to be an appropriate approach to 
evaluate the long-term cost-effectiveness of systematic 
CAD screening strategy in T2DM subjects at a very high 
cardiovascular risk without known history of CAD. Of 
note, among 3.7 million people with diabetes in France, 
we estimate that at least 90,000 individuals will be eligible 
for our study in the SNDS database.
Cost‑effectiveness of routine CAD screening in patients 
with diabetes
Systematic CAD screening strategy leads to more inva-
sive examination, especially coronary angiography, which 
is associated with increased risk of complications [11, 
12]. Routine CAD screening encourages also revascu-
larizations and intensification of pharmacological treat-
ments, despite uncertainties in terms of related benefits. 
In the FACTOR-64 study, CAD screening was not asso-
ciated with a significant reduction in major cardiovas-
cular events despite intensive pharmacological control 
of cardiovascular risk factors (and some coronary revas-
cularizations) in patients with a positive screening test, 
while individuals assigned to control group and those 
with a negative screening test had only conventional 
cardiovascular treatment goals [13]. Furthermore, BAR-
DOT (Basel Asymptomatic high-Risk Diabetics’ Out-
come Trial) study showed that combined medical therapy 
and invasive strategy (coronary angiography followed or 
not by revascularization) for silent CAD, compared with 
medical treatment alone, was associated with reduced 
scintigraphic CAD progression, but no significant dif-
ference was observed in terms of hard clinical events in 
high risk T2DM patients [28]. Therefore, to avoid unjus-
tified health expenses and misuse of collective resources 
associated with routine CAD screening, we conduct the 
SCADIAB study to assess the cost-effectiveness of this 
strategy in people with T2DM and a very high cardiovas-
cular risk.
Strengths and limitations
The key strength of our study is the collection of a com-
prehensive range of clinical features, cardiovascular pro-
cedures, history of pharmacological therapies or surgery, 
major events and survival status in the whole French pop-
ulation of patients with T2DM and a very high cardiovas-
cular risk during an overall period of 12 years. SCADIAB 
findings will have a broader generalizability for all T2DM 
patients at a very high cardiovascular risk. Our study 
will provide a line of complementary evidence (further 
to RCTs’ findings) in terms of routine CAD screening in 
a contemporary cohort of patients with T2DM in real-
world settings. SCADIAB will be more economical and 
time efficient than RCT, but a number of intrinsic limi-
tations need to be acknowledged. The retrospective and 
non-randomized design of our study is subject to bias 
(selection, information, detection) and confounding fac-
tors. To limit selection bias, our study population will be 
rigorously defined using pre-specified inclusion criteria 
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(T2DM for at least 7 years, with at least 2 cardiovascu-
lar risk factors and one or more organ damage) extracted 
from reliable and valid SNDS database. The 7-year selec-
tion period leading to assignment of each individual to 
one of the two study arms (CAD screening or absence 
of CAD screening) will limit information bias. We will 
use validated algorithms to identify inclusion criteria 
and endpoints [29–31]. Also, the cardiovascular inves-
tigation required for study arms assignment (stress test, 
scintigraphy, stress echocardiography…) will be recorded 
exhaustively in the SNDS database. We believe that the 
detection bias will be limited in our study as we have 
access to the SNDS database covering the whole French 
population including death registry. Finally, we will use 
the hdPS method to control measurable confounding fac-
tors as well as unknown or unmeasurable ones [32–34].
Conclusions
SCADIAB study is the first investigation of the cost-effec-
tiveness of CAD screening strategy in T2DM patients 
with a very high cardiovascular risk. It will evaluate the 
economic impact and clinical benefits of routine CAD 
screening in this population. It will also evaluate the clin-
ical practice regarding CAD screening. SCADIAB will 
provide essential information for payers, clinicians, and 
scientific societies in terms of long-term efficiency of sys-
tematic CAD screening in a large T2DM population. Our 
study will also measure the economic performance of 
CAD screening in a real-world setting, with an accurate 
comparison with no CAD screening strategy. The SCA-
DIAB findings will help to optimize the use of health care 
resources and guide clinical decision-making and future 
recommendations.
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